Rhizen Pharmaceuticals

Focus: Rhizen Pharmaceuticals is a Swiss-headquartered biotech company founded in 2008 focused on small molecule development in neurology and oncology. The company operates as a clinical-stage biotech with a diversified pipeline across hematologic and solid tumors.

Neurology

Profile data last refreshed 2d ago · AI intelligence enriched 1w ago

Open Jobs

About Rhizen Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Rhizen Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

17 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RP12146

Solid Tumor

Phase 1

Clinical Trials (1)

NCT05002868Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors

Phase 1

Help build intelligence for Rhizen Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diverse pipeline with 17 active programs spanning Phase 1/2, including multiple shots on goal with Tenalisib across hematologic malignancies and breast cancer
Basel headquarters provides access to world-class pharma ecosystem and collaboration opportunities with global leaders
Small molecule focus offers deep chemistry and pharmacology expertise in oncology and neurology domains

Watch Out For

Zero current job openings signals potential hiring freeze, organizational contraction, or underfunding challenges
Early-stage pipeline with no Phase 3 programs and no marketed products means no revenue visibility or near-term commercial catalysts
Limited public financial data and private funding information create transparency concerns about company stability and runway

Generated by Claude from Rhizen Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

RP7214

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04680429A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects

Phase 1

RP6530

Healthy

Phase 1

Clinical Trials (1)

NCT02690727To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers

Phase 1

RP6530

Lymphoma, B-Cell

Phase 1

Clinical Trials (1)

NCT02017613Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies

Phase 1

Tenalisib

Classical Hodgkin Lymphoma

Phase 1

Clinical Trials (1)

NCT03471351Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

Phase 1

RP6530

Lymphoma, T-Cell, Peripheral

Phase 1

Clinical Trials (1)

NCT02567656Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Phase 1

RP4010

Lymphoma

Phase 1

Clinical Trials (1)

NCT03119467Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

Phase 1

Tenalisib

T Cell Lymphoma

Phase 1/2

Clinical Trials (1)

NCT03770000Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Phase 1/2

RP3128

Healthy Volunteers

Phase 1/2

Clinical Trials (1)

NCT02958982Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals

Phase 1/2

Tenalisib

Hematological Malignancies

Phase 1/2

Clinical Trials (1)

NCT03711604Compassionate Use Study of Tenalisib (RP6530)

Phase 1/2

RP7214

Myelodysplastic Syndromes

Phase 1/2

Clinical Trials (1)

NCT05246384Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

Phase 1/2

Tenalisib 800mg

Locally Advanced Breast Cancer

Phase 2

Clinical Trials (1)

NCT05021900Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2

Tenalisib

Leukemia, Lymphocytic, Chronic, B-Cell

Phase 2

Clinical Trials (1)

NCT04204057Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 2

Tenalisib,

Non Hodgkin Lymphoma

Phase 2

Clinical Trials (1)

NCT03711578Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

Phase 2

Tenalisib

Peripheral T Cell Lymphoma

Phase 2

Clinical Trials (1)

NCT05239910Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

Phase 2

Tenalisib

Triple Negative Breast Cancer (TNBC)

Phase 2

Clinical Trials (1)

NCT06189209Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)